Pacira BioSciences
PCRX
239 hedge funds and large institutions have $772M invested in Pacira BioSciences in 2024 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 87 increasing their positions, 69 reducing their positions, and 87 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 69
17% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $5.74M
0.32% less ownership
Funds ownership: 111.48% → 111.16% (-0.32%)
15% less funds holding
Funds holding: 280 → 239 (-41)
46% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 87
48% less capital invested
Capital invested by funds: $1.48B → $772M (-$712M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$47.9M |
| 2 |
D.E. Shaw & Co
New York
|
+$25.2M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$18.8M |
| 4 |
Morgan Stanley
New York
|
+$18.5M |
| 5 |
DPCM
Doma Perpetual Capital Management
Miami,
Florida
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$52.6M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$44.8M |
| 3 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
-$39.2M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$23.1M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$17.6M |
PCRX Hedge Fund Activity: Q3 2024 in Review
239 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2024, worth a combined $772M — down 48% from $1.48B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of PCRX and 47 opened new positions — a net loss of 40 holders — while 69 trimmed existing stakes and 87 added.
The largest buyer was Pacer Advisors, adding an estimated $47.9M. The largest seller was Frontier Capital Management, exiting entirely with an estimated $52.6M sold.
- 239 institutional investors held Pacira BioSciences (PCRX) as of Q3 2024, down from 280 in Q2 2024.
- Funds reported $772M of Pacira BioSciences stock for Q3 2024, down 48% quarter-over-quarter.
- 47 funds opened new Pacira BioSciences positions in Q3 2024 and 87 closed out, a net change of -40 holders.
- The largest Pacira BioSciences buyer in Q3 2024 was Pacer Advisors, an estimated $47.9M added.
- The largest Pacira BioSciences seller in Q3 2024 was Frontier Capital Management, an estimated $52.6M sold.
Based on aggregated 13F filings for Q3 2024.